Bovie Medical Corporation Announces FDA Clearance to Market the Bovie IDS 300-Watt Electrosurgical Generator

Article

MELVILLE, N.Y. -- Bovie Medical Corporation, a manufacturer and marketer of electrosurgery products, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to commence manufacturing and marketing of the Bovie IDS-300 for use in general surgeries and other minimally invasive surgical procedures.

The high frequency generator features both monpolar and bipolar functions combined with 300 watts of cutting power. The Bovie IDS-300 was specifically designed for today's operating room and surgi-center market. Deliveries of the IDS-300 will commence during the first quarter of FY 2003, and are expected to contribute in excess of $2.0 million to Bovie's current fiscal year revenues.

The FDA clearance places Bovie in a solid position to maximize the reputation of the "Bovie" name in electrosurgery. Early demand for the Bovie IDS-300 watt generator, which is a fully-digital electrosurgical unit with many physician friendly features, indicates that FY 2003 will be one of increased sales and profitability. The company also announced that it expects to report increased revenues for FY 2002. Revenues for FY 2001 were $11.5 million.

Source: Bovie Medical Corporation

Related Videos
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Vaccine conspiracy theory vector illustration word cloud  (Adobe Stock 460719898 by Colored Lights)
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Related Content